Prostate Specific Antigen at the Initial Diagnosis of Metastasis to Bone in Patients After Radical Prostatectomy

Journal of Urology

Volumn 184, Issue 1, 2010, Pages 157-161

  Loeb, Stacy ^a   Makarov, Danil V ^a   Schaeffer, Edward M ^a   Humphreys, Elizabeth B ^a   Walsh, Patrick C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

bone and bones; neoplasm metastasis; prostate specific antigen; prostatectomy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL FEATURE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATECTOMY; RETROSPECTIVE STUDY; SYMPTOM;

ADULT; AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 77953120700     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.03.033     Document Type: Article

References (16)

1. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
2. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf Accessed January 21, 2009
4. Mehta S.S., Lubeck D.P., Sadetsky N., et al. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol 171 (2004) 215
5. Hirobe M., Takahashi A., Hisasue S., et al. Bone scanning-who needs it among patients with newly diagnosed prostate cancer?. Jpn J Clin Oncol 37 (2007) 788
6. Makarov D.V., Humphreys E.B., Mangold L.A., et al. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol 179 (2008) 156
7. Moul J.W., Wu H., Sun L., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141
8. Parekh D.J. Commentary on early hormonal therapy for PSA only recurrence after radical prostatectomy-success towards survival or antidote to anxiety?. J Urol 179 (2008) S60
9. Nelson C.J., Lee J.S., Gamboa M.C., et al. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 113 (2008) 1097
10. Smith M.R., Kabbinavar F., Saad F., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23 (2005) 2918
11. Loblaw D.A., Virgo K.S., Nam R., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25 (2007) 1596
12. Walsh P.C., DeWeese T.L., and Eisenberger M.A. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 166 (2001) 508
13. Lai M.H., Luk W.H., and Chan J.C. Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population. Urol Oncol (2009) Epub ahead of print
14. Chybowski F.M., Keller J.J., Bergstralh E.J., et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145 (1991) 313
15. Wolff J.M., Bares R., Jung P.K., et al. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int 56 (1996) 169
16. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27 (2009) 4300